Seer, Inc., launched today to capture and translate molecular insights from the proteome to enable early detection of cancer and neurological diseases and drive earlier treatment to improve patient outcomes. Seer’s core technology, the Proteograph™ platform, is designed to provide rapid, cost-effective, and broad-scale proteomic profiling with high accuracy.
December 17, 2018
· 8 min read